ArticleCureus2024
Comparison of Efficacy, Safety, and Economic Outcomes Between Biosimilar ABP 215 and Originator Bevacizumab in Japanese Patients With Colorectal Cancer.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Bevacizumab is one of the most effective anticancer treatment options for patients with unresectable advanced or recurrent colorectal cancer. The high cost of the drug has been a barrier to its use, but in recent years, biosimilars with lower prices have been launched in Japan. This study compared the efficacy, safety, and cost-effectiveness of the originator and biosimilar products in Japanese patients with colorectal cancer. Methods This is a single-center, retrospective, observational cohort study including patients diagnosed with colorectal cancer who received the originator bevacizumab (Avastin®) or a biosimilar ABP 215 between January 2018 and April 2024. Enrolled colorectal cancer patients were divided into two cohorts: those who only received the originator and those who received only the biosimilar ABP 215 until the end of bevacizumab therapy. Efficacy was evaluated in terms of progression-free survival (PFS) over a two-year follow-up period. Adverse events were graded using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Results A total of 159 patients were eligible for this study and divided into the originator cohort (n=121) and the biosimilar ABP 215 cohort (n=38). The Kaplan-Meier curves and a log-rank test showed no significant differences in median PFS between the originator and biosimilar ABP 215 cohorts (8.41 months [95% CI, 7.33-9.43] and 7.13 months [95% CI, 5.03-9.66], respectively,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.